Objectives: To determine the antimicrobial activity of ALX-009, a combination of bovine lactoferrin and hypothiocyanite, in sputum against Pseudomonas aeruginosa and Burkholderia cepacia complex (Bcc), key pathogens causing infection in the lungs of cystic fibrosis (CF) patients.
Introduction
Cystic fibrosis (CF) is characterized by chronic polymicrobial airway infection and inflammation which is the major cause of morbidity and mortality. 1 Although Pseudomonas aeruginosa is the most frequently isolated CF respiratory pathogen, 2 infection with other bacteria, including Staphylococcus aureus, Burkholderia cepacia complex (Bcc), Stenotrophomonas maltophilia and Achromobacter xylosoxidans, also occurs. 2 Many of these bacteria are constitutively resistant to a range of antibiotics. Moreover, frequent use of antibiotics for suppression of bacterial growth and treatment of exacerbations results in further development of resistance. [2] [3] [4] [5] In a recent study in northern Europe, 60% of CF P. aeruginosa isolates were MDR, with resistance to penicillins and cephalosporins being most common. 6 There is a clear unmet need for novel antimicrobial agents to treat respiratory infections, particularly those caused by P. aeruginosa and Bcc, in CF patients. One such antimicrobial is ALX-009, an investigational inhaled product in development by Alaxia (Lyon, France) for treatment of bacterial respiratory infections. ALX-009 is a combination of bovine lactoferrin (bLF) and hypothiocyanite (OSCN # ). LF is an antimicrobial protein found in airway secretions; 7 however, it has been detected at low levels in the CF lung, and levels are further depleted in patients colonized with P. aeruginosa owing to degradation by proteases. 8 Hypothiocyanite is a bactericidal agent that is produced naturally as part of the oxidative lactoperoxidase-hydrogen peroxide-thiocyanate system. 9 In CF, this system is defective and the bactericidal OSCN # cannot form. 10 ALX-009 has been recently shown to have in vitro bactericidal activity against a range of CF pathogens, including P. aeruginosa (n " 52), MDR P. aeruginosa (n " 20) and Burkholderia spp. (n " 165). 11 Furthermore, ALX-109 (8000 mg/L apo-bLF and 100 lM OSCN # ) prevents biofilm formation by P. aeruginosa on airway epithelial cells. 12 Moreover, although in vitro studies have reported contradictory results with respect to the cytotoxicity of LF, 12-14 a recent safety study in which ALX-009 was administered daily to rats and dogs for up to 6 and 9 months, respectively, reported no histological signs indicative of cell death. 15 In this study, we determined the activity of ALX-009 against clinical respiratory P. aeruginosa isolates grown planktonically under aerobic and anaerobic conditions. To determine both efficacy under physiologically relevant conditions and potential synergy with tobramycin, an antibiotic currently used to treat lung infection in CF patients, we treated sputum from CF patients with ALX-009, alone and in combination with tobramycin, and determined the effect on bacterial density of P. aeruginosa, and Bcc and total sputum bacterial density.
Materials and methods

Materials
OSCN
# and bLF solutions were prepared, according to an Alaxia SAS standard operating procedure, and mixed to give a final concentration of ALX-009 (OSCN # 130 mg/L; bLF 8000 mg/L) which corresponded to the MIC 90 for a large collection of clinical isolates previously tested. 11, 16 Tobramycin sulphate (USP grade), obtained from Chonqing Biochem, China, was dissolved in sterile water to achieve a stock solution of 10000 mg/L. Glucose-6-phosphate (G6P) and potassium nitrate were both purchased from Sigma-Aldrich (Gillingham, UK). P. aeruginosa-selective agar (PASA) and B. cepacia-specific agar (BCSA) were purchased from Fannin Healthcare (Leopardstown, Ireland). Mueller-Hinton agar (MHA, Oxoid Ltd, Basingstoke, UK) and Mueller-Hinton broth (MHB; Oxoid Ltd, Basingstoke, UK) were supplemented with 1% (w/v) potassium nitrate when testing P. aeruginosa to act as the terminal electron receptor and allow for anaerobic respiration. G6P was added to the media at a final concentration of 25 mg/ L for all time-kill assays.
Bacterial isolates
The P. aeruginosa isolates (B023 V4S2C, B002 V1S1A, B060 V1S1K and B008 V1S1C) used in the study were cultured from the sputum of four different CF patients at the Adult CF Centre, Belfast Health and Social Care Trust. Isolates were cultured on Supplemented Brucella Blood Agar at 37 C under aerobic conditions for 24 h prior to use.
Time-kill studies
Time-kill experiments were performed in MHB according to CLSI standards 17 to determine the activity of ALX-009 against P. aeruginosa isolates. Bacterial cultures, at a final inoculum of 5%10 5 cfu/mL, were incubated with ALX-009 at 37 C under aerobic or anaerobic conditions. Killing activity was assessed at 0, 1, 3, 6 and 24 h by carrying out serial dilutions (10 #1 -10
#6
) in quarter strength Ringer's solution (QSRS) followed by enumeration on MHA. A no-drug control was run in each assay. Bactericidal activity was defined as a 3 log 10 reduction in colony-forming units (cfu/mL) compared with the original inoculum. 18 Sputum sample collection and processing Anonymized sputum samples, which would otherwise have been disposed of, were collected from CF patients during physiotherapy treatment at the Adult CF Centre, Belfast Health and Social Care Trust. Permission to use these anonymized sputum samples was given by the Director of R&D of the Belfast Health and Social Care Trust. Immediately upon sample receipt, an aliquot was homogenized by repeated passage through a 1 mL syringe (BD Plastipak, Franklin Lakes, NJ, USA) without a needle. Aliquots (100 lL) were spread plated on PASA or BCSA, for selection of P. aeruginosa and Bcc, respectively, and on blood agar plates to confirm bacterial growth in the sample. Plates were incubated until growth was visible for a maximum of 3 days. Growth of P. aeruginosa or Bcc on selective plates was confirmed by 16S rRNA sequencing as described previously. 19 The susceptibility of P. aeruginosa isolates, cultured from these samples, to tobramycin was determined by Etest V R according to the manufacturer's instructions. Additional aliquots of each sputum sample were stored at #80 C until required for further use.
Antimicrobial activity of ALX-009 against P. aeruginosa and Bcc in CF sputum Sputum samples (n " 24, P. aeruginosa positive; n " 9, Bcc positive) were allowed to thaw on ice. No sputum samples were positive for both P. aeruginosa and Bcc. Sputum plugs were selected and homogenized as described above. Aliquots (0.5 mL) were added to tubes containing 4.5 mL of ALX-009, tobramycin, ALX-009 and tobramycin, or PBS (control). Tobramycin was used at a final concentration of 8 mg/L with 4 lL of tobramycin stock solution added to either sterile PBS or ALX-009 to determine the activity of tobramycin alone and in combination with ALX-009, respectively. Samples were vortex mixed and incubated at 37 C for 24 h under aerobic conditions. At 0, 6 and 24 h, aliquots (100 lL) were removed, serially diluted in QSRS solution and plated on both non-selective blood agar and PASA or BCSA plates. Drug carry-over was minimized by carrying out serial dilutions (10
) in sterile QSRS. Following overnight incubation in air, P. aeruginosa/Bcc density and total bacterial density were determined with P. aeruginosa and Bcc identified as described above. A reduction, by any of the agents/combinations under test, of the original bacterial density by 3 log 10 cfu/g sputum was considered bactericidal. Synergy was defined, according to CLSI guidelines, as a 2 log 10 decrease in bacterial density at 24 h by the combination compared with that by the most active single agent and as a 2 log 10 decrease in bacterial density compared with the starting bacterial density. 17, 18 Results for time-kill assays are expressed as median cfu/g sputum with range.
Effect of treatment with two doses of ALX-009 on microbial load in CF sputum
In clinical practice, it is likely that ALX-009 would be administered twice daily in a similar dosing regimen to other currently available inhaled antibiotics such as tobramycin and colistin. To determine the effect of treating sputum with a second dose of ALX-009, aliquots from an additional 10 sputum samples positive for P. aeruginosa for were treated with one (t " 0 h) or two doses (t " 0 h, t " 12 h) of ALX-009 or control. Following addition of test agents, aliquots (100 lL), were removed at 0, 6 and 24 h after the first dose, and at 0, 6 and 22 h after the second dose, which corresponded to 12, 18 and 34 h after initial treatment. Aliquots were serially diluted and plated, and P. aeruginosa and total bacterial density were determined as described above.
Statistical analysis
Comparison of P. aeruginosa, Bcc and total sputum bacterial density between treatment groups was performed by the Friedman test with posthoc tests performed using the Wilcoxon signed-rank test with Bonferroni adjustment for multiple groups applied. Spearman's rank was used to determine if there was a correlation between either initial P. aeruginosa sputum bacterial density or tobramycin MIC for P. aeruginosa isolates and P. aeruginosa density following treatment for 24 h with a single dose of ALX-009 or tobramycin.
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Results
Antimicrobial activity of ALX-009 against clinical P. aeruginosa isolates under aerobic and anaerobic conditions
The bactericidal activity of ALX-009 was dependent on the P. aeruginosa isolates tested (Figure 1 ). For two of the isolates, killing was rapid; bacterial numbers decreased to below the detectable limit after 2 h with no further growth detected at subsequent timepoints ( Figure S1 , available as Supplementary data at JAC Online). However, for the other two isolates ( Figure S1 ), although initial killing was rapid with bacterial numbers decreasing to below the detection limit after 2 h, further growth was apparent at 24 h. At 24 h, ALX-009 demonstrated bactericidal activity against all four isolates under aerobic conditions, and against three of these four isolates under anaerobic conditions.
Antimicrobial activity of ALX-009 against P. aeruginosa in CF sputum ALX-009 demonstrated bactericidal activity against P. aeruginosa in sputum samples (n " 24) at 6 and 24 h (Figure 2a) . At 6 h, bactericidal activity was apparent in 22/24 samples, with P. aeruginosa sputum density below the detectable limit in 12/24 samples. At 24 h, bactericidal activity was apparent for 14/24 samples, with P. aeruginosa sputum density below the detectable limit in 10/24 samples. There were significant differences (P , 0.001) in P. aeruginosa sputum density between the four treatments at 6 and 24 h. At 6 h, the median P. aeruginosa sputum density was significantly lower (P , 0. (Figure 2c) . ALX-009 also demonstrated significantly greater bactericidal activity than tobramycin at both 6 h (P , 0.001) and 24 h (P " 0.004). Tobramycin demonstrated bactericidal activity against P. aeruginosa in 3/24 samples, and bacteriostatic activity against P. aeruginosa in 2/24 samples at 24 h; however, P. aeruginosa density was only reduced below the detectable limit in one sample.
Changes in P. aeruginosa density following treatment with ALX-009 reflected initial P. aeruginosa density in the sample. In the 10 samples in which P. aeruginosa density was reduced below the detectable limit at 24 h, initial P. aeruginosa density was 10 4 cfu/g sputum (median, 1.17%10 4 ; range, 4%10 3 -1.45%10
6 cfu/g sputum). In contrast, for the remaining 14 samples, in which P. aeruginosa was detected at 24 h, initial P. aeruginosa density was higher at 10 6 cfu/g sputum (median, 1. 7 cfu/g sputum). There was a significant correlation (Spearman's q " 0.6128, P " 0.0015) between the initial P. aeruginosa density in sputum and the P. aeruginosa density in sputum at 24 h following treatment with ALX-009.
The susceptibility to tobramycin of the most prevalent P. aeruginosa morphotype in each of the 24 P. aeruginosa-positive samples was determined; 10 isolates were resistant to tobramycin, with the remaining 14 isolates being susceptible (Table S1 ). There was no correlation between tobramycin MIC and P. aeruginosa density at 24 h following treatment with either tobramycin (Spearman's q " 0.353, P " 0.091) or ALX-009 (Spearman's q " #0.03, P " 0.8879).
Given the bactericidal activity of ALX-009 against P. aeruginosa in sputum, in the majority of samples, it was not possible to determine if there was a synergistic effect when ALX-009 was combined with tobramycin. However, synergy was apparent for four samples at 24 h ( Figure S2 ).
The effect of ALX-009 on total sputum bacterial density was less than that observed for P. aeruginosa. However, there were statistically significant differences (P , 0.001) between the four test conditions at 6 h ( Figure 3a ) and 24 h (Figure 3b ). Post-hoc tests revealed that there were significant differences in the median total density when samples were treated with ALX-009 versus both control and tobramycin at both timepoints.
Antimicrobial activity of ALX-009 against Bcc in CF sputum
ALX-009 demonstrated activity against bacterial species in the Bcc (Burkholderia cenocepacia, n " 5; Burkholderia multivorans, n " 4) in sputum samples (Figure 4a ) but the magnitude of change in Bcc density following treatment was less than that for P. aeruginosa. The median Bcc density was significantly lower in ALX-009-treated (6 h, 6.80%10 4 cfu/g sputum; 24 h, 1.77%10 5 cfu/g sputum) versus control (6 h, 1.21%10 7 cfu/g sputum; 2.15%10 7 cfu/g sputum) samples; however, Bcc density was not reduced below the detectable limit in any sample at either timepoint. Tobramycin had no bactericidal activity against Bcc, and no synergy was apparent between ALX-009 and tobramycin for the five samples in which both agents were tested.
The effect of ALX-009 on total bacterial density in Bcc-positive samples was also determined (Figure 4b ). The median total density following treatment with ALX-009 (6 h, 7.20%10 5 cfu/g sputum; 24 h, 1.04%10 7 cfu/g sputum) was significantly less than the untreated control (6 h, 3.70%10 7 cfu/g sputum; 24 h, 1.04%10 7 cfu/g sputum). In contrast, tobramycin had no effect on total bacterial density in Bcc-positive sputum samples.
Effect of treatment with a second dose of ALX-009 on bacterial density in CF sputum
To determine the effect of treating sputum with a second dose of ALX-009, aliquots of a further 10 P. aeruginosa-positive sputum Antimicrobial activity of ALX-009 JAC samples were treated with one (t " 0 h) or two doses (t " 0 h, t " 12 h) of ALX-009; treatment with two doses resulted in bactericidal activity in 7/10 samples at 34 h compared with only 3/10 samples with one dose (Figure 5a ). There were significant differences (P , 0.001) between the three treatment groups at 12, 18, 24 and 34 h ( Figure S3 ). There were also significant differences (P , 0.001) in total sputum bacterial density between the three treatment groups at 12, 18, 24 and 34 h (Figure 5b , Figure S4 ). For both P. aeruginosa ( Figure S3 ) and total ( Figure S4 ) sputum density, post-hoc tests demonstrated significant differences between control and both one and two doses, and also between one dose and two doses.
Discussion
ALX-009, a novel antimicrobial compound composed of OSCN # and bLF, was granted orphan drug status in 2009 and is currently under evaluation for aerosol administration in people with CF with chronic respiratory infection. This study investigated the antimicrobial activity of ALX-009, alone and in combination with tobramycin, against CF respiratory pathogens in sputum.
Given that sputum within the lungs of CF patients contains anaerobic microenvironments, 20 and that hypoxic environments affect the activity of some classes of antibiotics, [21] [22] [23] we initially examined activity under both aerobic and anaerobic conditions. In time-kill assays, ALX-009 demonstrated bactericidal activity against P. aeruginosa isolates under both aerobic and anaerobic conditions. These results are consistent with previous studies that reported inhibitory and bactericidal activity of ALX-009, using broth microdilution and time-kill assays, respectively.
11,16 ALX-009 maintained activity against P. aeruginosa under anaerobic conditions, suggesting that antimicrobial activity would not be decreased under anaerobic conditions within the CF lung. This contrasts with the activity of some antibiotics currently used to treat CF lung infection, such as tobramycin, amikacin and aztreonam, for which MICs for P. aeruginosa are significantly higher under anaerobic conditions. [21] [22] [23] [24] To determine activity under conditions that are more physiologically relevant to in vivo conditions in the CF lung, we determined activity against key respiratory pathogens in CF sputum. CF sputum contains DNA, filamentous actin, mucin, bacteria and cell debris from bacterial, inflammatory and epithelial cells, 25 all of which can adversely affect the activity of antimicrobials. 26 Furthermore, it is widely recognized that bacteria grow in complex polymicrobial biofilms within CF sputum and that this causes increased resistance to antibiotics. [27] [28] [29] The stability of OSCN # and bLF in sputum is unknown. Moreover, owing to the complexity of the sputum matrix, specific and well-adapted analytical methods are required to measure both compounds, and such methods are not presently available. OSCN # has a short half-life of 1 h in buffered solutions 30 and therefore drug carry-over is not of concern. bLF has a longer half-life, and potential drug carry-over was accounted for by immediately carrying out serial dilutions in QSRS on removal of the sample aliquot. Treatment of sputum from CF patients with ALX-009 resulted in a significant decrease in the bacterial density of both P. aeruginosa and Bcc. The magnitude of effect was greater for P. aeruginosa than for Bcc, which is not unexpected given the inherent antimicrobial resistance of Bcc. 31 These findings support the results of a previous study that reported that ALX-109 reduced P. aeruginosa (PAO1) biofilm formation by 0.7 log units, corresponding to a killing of 60% of the bacteria compared with untreated control. 12 We also demonstrated synergy between ALX-009 and tobramycin against P. aeruginosa in sputum; however, this was only apparent in a small number of sputum samples Tunney et al.
owing to the excellent bactericidal activity of ALX-009. These results support previous findings reporting an additive effect for tobramycin or aztreonam in combination with ALX-109 when disrupting established P. aeruginosa biofilms, 12 and suggest that there could be a benefit to administering ALX-009 in combination with antibiotics.
Changes in P. aeruginosa density in sputum following a single treatment with ALX-009 reflected the initial P. aeruginosa density in the sample. To determine if differences in killing rates could be due to the presence of antibiotic-resistant P. aeruginosa and not an inoculum effect, we determined the susceptibility of P.
aeruginosa from each sputum sample to tobramycin. There was no correlation between tobramycin MIC and P. aeruginosa density following treatment with ALX-009 for 24 h, with ALX-009 demonstrating killing of both tobramycin-susceptible and tobramycin-resistant P. aeruginosa. This suggests that cross-resistance to ALX-009 from pre-existing antibiotic resistance mechanisms in P. aeruginosa is unlikely.
Given that changes in P. aeruginosa density in sputum, following a single treatment with ALX-009, reflected initial P. aeruginosa density in the sample, we hypothesized that repeated treatment with ALX-009 could further reduce P. aeruginosa airway bacterial density. Therefore, sputum samples, in which P. aeruginosa was present in a high load, were treated with two doses of ALX-009 12 h apart to mimic the timeframe routinely used for administration of currently inhaled antibiotics; addition of a second dose resulted in enhanced bactericidal activity against P. aeruginosa. However, further work is necessary to evaluate the effect of prolonged treatment with ALX-009 on P. aeruginosa airway bacterial density, and the potential for development of resistance to ALX-009 and cross-resistance to other antimicrobials.
Extended culture and molecular detection methods have demonstrated a complex and diverse microbiota in the CF airways [32] [33] [34] with loss of diversity associated with increasing age, reduced lung function and disease progression. [35] [36] [37] Therefore, agents that directly target CF pathogens, such as P. aeruginosa, without having bactericidal activity against other members of the airway Antimicrobial activity of ALX-009 JAC microbiota could be beneficial. In the present study, there was a significant decrease in the total sputum bacterial density following both a single dose and two doses of ALX-009. However, the magnitude of this decrease was less than that apparent for P. aeruginosa and the total bacterial density increased once treatment with ALX-009 was discontinued. This suggests that treatment with ALX-009 may have less effect on total bacterial burden, and may potentially have less effect on microbiota composition and structure. Detailed analysis of samples from future clinical studies would be required to better define the effect of treatment on airway community composition and structure, and to determine if the community fully recovers following completion of treatment.
There are a number of limitations to this study. Firstly, it would have been interesting to determine whether the use of a higher concentration of OSCN # or bLF in the combination would have demonstrated greater antimicrobial activity against Bcc species. The concentrations of OSCN # and bLF used corresponded to the MIC 90 for a large collection of clinical isolates previously tested. 11, 16 As clinical doses have not yet been defined, there is the potential to increase the dose of both OSCN # and bLF. Secondly, the number of Bcc-positive sputum samples available, and the volume of sputum received in the samples, were small. To better determine the activity of ALX-009 against Bcc a larger number of samples would be required, preferably of greater volume, to enable determination of possible synergy with antibiotics. Thirdly, as sputum samples were exposed to a maximum of two doses, we were not able to determine if isolates in sputum are likely to determine resistance to ALX-009. However, if ALX-009 were to be used clinically, it would be important to determine if resistance would develop with prolonged use. Furthermore, given that ALX-009 demonstrated bactericidal activity against P. aeruginosa under both aerobic and anaerobic conditions, it would also have been interesting and clinically relevant to determine activity in sputum under anaerobic conditions. However, this was not feasible owing to the number and volume of sputum samples available for testing.
In conclusion, this study has demonstrated the excellent antimicrobial activity of ALX-009 against P. aeruginosa isolates grown under both aerobic and anaerobic conditions. Moreover, it also clearly showed the bactericidal activity of ALX-009 against P. aeruginosa in sputum from CF patients. Therefore, ALX-009 demonstrates promise as a novel antimicrobial that could be used to treat MDR infections caused by P. aeruginosa in CF.
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